Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Angiogenic Study in Patients With Well/Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors Treated With Everolimus

NCT02305810 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT02305810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02305810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Angiogenic Study in Patients With Well/Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors Treated With Everolimus
Lead sponsor
European Institute of Oncology
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
June 30, 2018
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocrine tumour metastatic